BACKGROUND: To investigate racial differences in tumor burden (cancer volume, cancer percentage and cancer to PSA ratios) in a large cohort of men undergoing radical prostatectomy (RP). METHODS: Demographic, clinical and pathological data of patients undergoing RP between 1993-2010 were reviewed and compared between African-American (AA) and non African-American (nAA) men. Further assessments of pathological tumor burden (estimated tumor volume, percent of cancer involvement, and estimated tumor volume/PSA ratios) were performed across Gleason score categories. RESULTS: Of 4157 patients in the analysis, 604 (14.5%) were AA. Overall, AA patients were younger, had higher Gleason scores, PSA levels and incidence of palpable disease (all P < 0.001). Despite comparable prostate weights (39.4 vs. 39.6 g), AA men had higher percent cancer involvement and estimated tumor volume (all P < 0.001) but similar estimated tumor volume/PSA ratios ( P> 0.05). When stratified by Gleason scores, prostate weights were comparable; however, estimated tumor volume, percent cancer involvement and estimated tumor volume/PSA ratios were higher in AA men with low grade (≤ 6) prostate cancer (PCa), similar in intermediate grade (7-8) and lower in high grade (9-10) PCa compared to nAA men. CONCLUSIONS: In this large series, AA patients had higher disease burden (estimated tumor volume, percent cancer involvement, estimated tumor volume/PSA ratios) compared to nAA but this association was especially pronounced in low grade (Gleason ≤ 6) cancers. These data depict a complex picture of relations between race and tumor burden across the spectrum of PCa aggressiveness. Further investigation is warranted to understand the mechanisms of racial disparities in PCa.
BACKGROUND: To investigate racial differences in tumor burden (cancer volume, cancer percentage and cancer to PSA ratios) in a large cohort of men undergoing radical prostatectomy (RP). METHODS: Demographic, clinical and pathological data of patients undergoing RP between 1993-2010 were reviewed and compared between African-American (AA) and non African-American (nAA) men. Further assessments of pathological tumor burden (estimated tumor volume, percent of cancer involvement, and estimated tumor volume/PSA ratios) were performed across Gleason score categories. RESULTS: Of 4157 patients in the analysis, 604 (14.5%) were AA. Overall, AA patients were younger, had higher Gleason scores, PSA levels and incidence of palpable disease (all P < 0.001). Despite comparable prostate weights (39.4 vs. 39.6 g), AA men had higher percent cancer involvement and estimated tumor volume (all P < 0.001) but similar estimated tumor volume/PSA ratios ( P> 0.05). When stratified by Gleason scores, prostate weights were comparable; however, estimated tumor volume, percent cancer involvement and estimated tumor volume/PSA ratios were higher in AA men with low grade (≤ 6) prostate cancer (PCa), similar in intermediate grade (7-8) and lower in high grade (9-10) PCa compared to nAAmen. CONCLUSIONS: In this large series, AA patients had higher disease burden (estimated tumor volume, percent cancer involvement, estimated tumor volume/PSA ratios) compared to nAA but this association was especially pronounced in low grade (Gleason ≤ 6) cancers. These data depict a complex picture of relations between race and tumor burden across the spectrum of PCa aggressiveness. Further investigation is warranted to understand the mechanisms of racial disparities in PCa.
Authors: Michael S Leapman; Stephen J Freedland; William J Aronson; Christopher J Kane; Martha K Terris; Kelly Walker; Christopher L Amling; Peter R Carroll; Matthew R Cooperberg Journal: J Urol Date: 2016-06-25 Impact factor: 7.450
Authors: Karriem S Watson; Vida Henderson; Marcus Murray; Adam B Murphy; Josef Ben Levi; Tiffany McDowell; Alfreda Holloway-Beth; Pooja Gogana; Michael A Dixon; LeAndre Moore; Ivanhoe Hall; Alexander Kimbrough; Yamilé Molina; Robert A Winn Journal: Prog Community Health Partnersh Date: 2019
Authors: Alexis R Gaines; Elizabeth L Turner; Patricia G Moorman; Stephen J Freedland; Christopher J Keto; Megan E McPhail; Delores J Grant; Adriana C Vidal; Cathrine Hoyo Journal: Cancer Causes Control Date: 2014-05-31 Impact factor: 2.506
Authors: Zachary Klaassen; Lauren Howard; Martha K Terris; William J Aronson; Matthew R Cooperberg; Christopher L Amling; Christopher J Kane; Stephen J Freedland Journal: Cancer Epidemiol Date: 2015-10-06 Impact factor: 2.984
Authors: Hari T Vigneswaran; Luke Mittelstaedt; Alessio Crippa; Martin Eklund; Adriana Vidal; Stephen J Freedland; Michael R Abern Journal: Prostate Cancer Prostatic Dis Date: 2021-07-08 Impact factor: 5.554
Authors: Jennifer S Myers; Karin A Vallega; Jason White; Kaixian Yu; Clayton C Yates; Qing-Xiang Amy Sang Journal: BMC Cancer Date: 2017-07-11 Impact factor: 4.638
Authors: Taraswi Mitra Ghosh; Jason White; Joshua Davis; Suman Mazumder; Teeratas Kansom; Elena Skarupa; Grafton S Barnett; Gary A Piazza; R Curtis Bird; Amit K Mitra; Clayton Yates; Brian S Cummings; Robert D Arnold Journal: Front Pharmacol Date: 2021-12-06 Impact factor: 5.810